2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115004
    MM-433593 1006604-91-6 98%
    MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites.
    MM-433593
  • HY-115133
    ABT-116 1008529-42-7 98%
    ABT-116 is an orally active antagonist of transient receptor potential vanilloid type 1 (TRPV1). ABT-116 has analgesic efficacy. ABT-116 can be used for the research of neurological disease.
    ABT-116
  • HY-115139
    Fenadiazole 1008-65-7 98%
    Fenadiazole acts as a central nervous system agent to manage insomnia and dreaminess.
    Fenadiazole
  • HY-115272
    GSK894490A 1012035-06-1 98%
    GSK894490A is a non-peptide ghrelin receptor agonist.
    GSK894490A
  • HY-115371
    Butaperazine dimaleate 1063-55-4 98%
    Butaperazine dimaleate is an antipsychotic compound with activity for the detection of vanadium (V). Butaperazine dimaleate can react with vanadium (V) in a phosphoric acid medium to form a red radical cation. The absorption spectrum of butaperazine dimaleate reaches a maximum at 513 nm, which conforms to Beer's law and corresponds to a concentration range of 0.25-5.0 μg/ml. Butaperazine dimaleate has a sensitivity value of 6.1 ng/cm2 and is suitable for the analysis of vanadium steel, minerals, biological samples, and soil samples.
    Butaperazine dimaleate
  • HY-115375
    R 50595 hydrochloride 104860-61-9 98%
    50595 hydrochloride is a selective noncompetitive cisapride antagonist that interferes with the activity of cisapride and BRL 24924. R 50595 hydrochloride has no effect on the response to electrical stimulation at concentrations up to 3 X 10(-7) M. R 50595 hydrochloride antagonizes the effects of cisapride and BRL 24924 in a noncompetitive manner. R 50595 hydrochloride completely abolishes the effects of 5-HT at a concentration of 3 X 10(-7) M and also antagonizes the effects of 5-HT in a noncompetitive manner.
    R 50595 hydrochloride
  • HY-115431
    Antho-rwamide I 114056-25-6 98%
    Antho-rwamide I is a neuropeptide that can be isolated from the sea anemone Anthopleura elegantissima. Antho-rwamide I is resistant to nonspecific aminopeptidases, which increases the stability of the peptide after neuronal release.
    Antho-rwamide I
  • HY-115447
    Clobenpropit 145231-45-4 98%
    Clobenpropit is a potent histamine H3-receptor antagonist. Clobenpropit decreases dopamine release and increases histamine levels in the hypothalamus. Clobenpropit shows antipsychotic-like activities. Clobenpropit causes a resuscitating effect in rats subjected to the hemorrhagic shock.
    Clobenpropit
  • HY-115500
    PL265 1206514-50-2 98%
    PL265 is an orally active dual enkephalinase inhibitor. PL265 is a prodrug of PL254, which can simultaneously and efficiently inhibit neutral endopeptidase (Neprilysin) and Aminopeptidase N. PL265 can effectively protect and significantly increase the local concentration of enkephalins (such as Met-Enkephalin and Leu-Enkephalin) released by cells at the pain or inflammation sites, thereby activating μ and δ opioid receptors to produce a potent analgesic effect. PL254 can also inhibit leukotriene A4 hydrolase (LTA4H), which may contribute to its additional anti-inflammatory effect by reducing the production of pro-inflammatory mediator leukotriene B4 (LTB4). PL265 can be used in non-addictive chronic pain research.
    PL265
  • HY-115511
    PyP-1 1370527-16-4 98%
    PyP-1 is a highly selective and potent PDE10 inhibitor. PyP-1 has a strong inhibitory effect on human PDE10A2 enzyme (Ki = 0.32 nM). PyP-1 can improve cognitive behavior. PyP-1 commonly used in research on conditions such as schizophrenia and cognitive impairment.
    PyP-1
  • HY-115606
    ML077 1135304-61-8 98%
    ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC50 for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC50 > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion.
    ML077
  • HY-115674
    ML175 610263-01-9 98%
    ML175 is a specific glutathione transferase Omega 1-1 (GSTO1-1) inhibitor. ML175 can significantly activate Akt and MEK1/2 kinases. ML175 can be used in the research of diseases such as Parkinson's disease.
    ML175
  • HY-115706
    13-Dilignoceroyl glycerol 120639-92-1 98%
    13-Dilignoceroyl glycerol is a diacylglycerol containing lignoceric acid (HY-121883 ) at the sn-1 and sn-3 positions. Lignoceric acid is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy research.
    13-Dilignoceroyl glycerol
  • HY-115724
    FPPQ 1648745-46-3 98%
    FPPQ is a dual-acting 5-HT3 (Ki = 0.9 nM) and 5-HT6 (Ki = 3 nM) receptor antagonist with antipsychotic and procognitive properties.
    FPPQ
  • HY-115739
    RTIL 13 1009376-10-6 98%
    RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 μM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively.
    RTIL 13
  • HY-115750
    Nω-allyl-L-arginine 139461-37-3 98%
    Nω-allyl-L-arginine is a competitive and reversible inhibitor of bovine brain nitric oxide synthase (nNOS). Nω-allyl-L-arginine can inactivate nNOS in a time-dependent manner. Nω-allyl-L-arginine also is a substrate, producing L-arginine, acrolein, and H2O.
    Nω-allyl-L-arginine
  • HY-115753
    Calpain Inhibitor-1 1448429-06-8 98%
    Calpain Inhibitor-1 (compound 36) is a potent and selective cysteine protease calpain 1 (Cal1) inhibitor (IC50=100 nM; Ki=2.89 μM).
    Calpain Inhibitor-1
  • HY-115760
    Okadaic acid ammonium salt 175522-42-6 98%
    Okadaic acid ammonium salt, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid ammonium salt has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid ammonium salt increases of phosphorylation of a number of proteins by inhibiting PP, and acts as a tumor promoter. Okadaic acid ammonium salt induces tau phosphorylation.
    Okadaic acid ammonium salt
  • HY-115763
    3-Aminopropylphosphinic acid 103680-47-3 98%
    3-Aminopropylphosphinic acid (3-APPA) is a phosphonic analog of GABA. 3-Aminopropylphosphinic acid is a potent, selective GABAB receptor agonist.
    3-Aminopropylphosphinic acid
  • HY-115764
    nAChR agonist 2 252870-46-5 98%
    nAChR agonist 2 (compound 8) is a selective alpha4beta2 (α4β2) nAChR agonist (Kd=26 nM).
    nAChR agonist 2
Cat. No. Product Name / Synonyms Application Reactivity